Figure 5.

Anlotinib therapy suppressed tumor angiogenesis in MM PDXs. Tumor-bearing NDG mice were prepared and treated as described in Figure 4. Mice were intravenously injected with 200 μg Ho33342 five minutes before tumor harvest. Tumor tissues were sectioned and stained with anti-CD31 antibody. (A) Representative images indicated tumor vessel density (red) and tumor vessel perfusion (blue) in myeloma PDX1 and PDX2. Scale bar: 100 μm. (B) Quantification of tumor vessel density and tumor vessel perfusion. (C) Representative images of whole tumor tissues showed CD31 staining and Ho33342 perfusion in PDX2. Scale bar: 1000 μm. PDX, patient-derived xenograft; Ctr, control group; Anlo, anlotinib treatment group; MFI, mean fluorescence intensity; CD31, an endothelial cell marker. Sytox green (green): cell nuclei. The intensity of Ho33342 perfusion reflects tumor vascular function. Data were from one experiment representative of two independent experiments with similar results. Data were shown as mean ± SD. Significance was determined by unpaired two-tailed Student’s t-test. **P < 0.01.